HARMS REPORTED BY PEOPLE
Which Sermorelin side effects people reported
Most reported harms were mild. Sore skin and joint pain led the list, while proof past 12 months stayed thin.
What harms appeared after Sermorelin shots
Most reported harm was mild. Serious trouble was rare, while sore skin and brief headaches came up most [14].
A 2024 review also listed joint pain and red or itchy skin. Some people had sore limbs, swelling, or muscle pain [14].
Longer studies help, but they can’t settle long use. In 2001, older adults got about 14 millionths of a gram per kilo of body weight at night for 5-6 months.
Swelling and joint pain were very rare [4]. A 2004 trial gave 1 milligram twice daily for 12 weeks to 31 men with HIV.
The men handled the shots well [10]. A 1996 trial followed 110 children for up to 12 months.
Their fasting blood sugar stayed normal [2]. Their fasting blood sugar stayed normal, so the study found no problem with blood sugar control.
You can see what happened in each group. Your risk still depends on your health and care.
What can go wrong while using Sermorelin
IGF-1 isn’t a blood test. It’s a hormone made mostly by the liver after growth hormone arrives.
Most trouble happened near the shot. Studies name red, itchy, or sore skin, plus headache, flushing, dizziness, and nausea.
Some people also held extra fluid or had joint pain [14]. Higher study amounts and a person’s health may change the chance.
Less than 4% of a skin shot reached blood [14]. The study didn’t show that the rest caused harm beneath the skin.
That low share wasn’t itself a reported harm. Pills haven’t worked in human trials.
One sleep result moved the wrong way. In 2001, people rated sleep slightly worse while a liver-made growth hormone rose [4].
The authors couldn’t explain why. Later work hasn’t settled the question.
What long use of Sermorelin shows; Rx means prescription
Long-term safety data in humans is limited; the longest reported tolerability data comes from studies of 5-6 months (Vitiello 2001) and 12 months (Thorner 1996 pediatric trial, Ogilvy-Stuart 1997). Extended placebo-controlled studies beyond 6 months in healthy aging adults have not been published since the 2008 Geref market withdrawal [4][2][16].
The Walker 2006 review in Clinical Interventions in Aging noted the theoretical safety advantage of preserved pituitary feedback: because somatostatin and IGF-1 continue to regulate GH output under sermorelin administration, the risk of supraphysiological GH/IGF-1 exposure — and any downstream consequences — is substantially reduced compared to exogenous GH [5]. The 12-month Makimura GHRH analog RCT (class-level evidence) showed no significant perturbation of glucose homeostasis over 12 months [12]. The absence of published long-term sermorelin-specific data is a genuine gap; existing evidence spans 5-12 months.
Where does that leave sermorelin outside a trial? Compounded injections for patients need an individual prescription; research-labelled material is still sold for lab work. With no approved retail product since 2008, 503A compounding is one route for a patient-specific medicine. At mypromise.com, Promise Peptides prescribes sermorelin as prescription-only care, with a licensed U.S. clinician deciding each case. Some requests are declined. The service sees U.S. patients, and what it offers changes across states and across treatments. The compounded medicine has no FDA approval; medical oversight cannot supply the long-term evidence missing from these studies.
Who Sermorelin studies left out
Some people couldn’t join the studies. That included people with active cancer, low thyroid hormone, or a past bad reaction to related drugs.
Child studies also checked the growth plates at the ends of bones. Bone age stayed on track in the 1996 trial [2].
Trouble in your growth gland or thyroid can weaken the response. That leaves no clear study answer for some people.
Sports rules add a separate bar. Drug-testing groups ban Sermorelin both during and outside a contest [1].
A medical pass is written leave from the sport’s drug-testing group. Without that leave, medical need doesn’t erase the ban.
What other medicines may weaken Sermorelin
IGF-1 isn’t a blood test. It’s a hormone made mostly by the liver after growth hormone arrives.
Steroid drugs used for swelling may weaken Sermorelin. Researchers think steroids make your brain hold back your growth gland [13].
An animal test used dexamethasone, a strong steroid [13]. An unnamed second drug stopped that hold, so growth hormone rose again.
That finding came from animals. It can’t tell you how your own steroid and Sermorelin would act together.
In a 2017 human study, two growth-hormone drugs came with Sermorelin and testosterone [9]. Since all were given together, nobody could split their effects.
Insulin and thyroid hormone may change IGF-1 too. These studies don’t give you a safe mixing list.
What health problems left a gap in Sermorelin studies
Trials didn’t include people with active cancer or low thyroid hormone [2][14]. They also left out people who had reacted badly to related drugs.
Low thyroid hormone can weaken your growth gland’s response. You’ll find a real gap for those health problems.
Geref child studies began with a thyroid check. The old approval covered children shown to lack growth hormone.
It wasn’t meant for every short child.
How safe Sermorelin looked in each study group
Most people in the studies handled Sermorelin well. Serious harm was rare [14].
The usual problems were sore skin at the shot, joint pain, swelling, and muscle pain [14]. One Sermorelin trial followed 110 children for 12 months.
Their fasting blood sugar stayed normal [2]. That means the test found no harm in how their bodies handled blood sugar.
The catch is that the groups differed. Children got 30 millionths of a gram per kilo of body weight at bedtime.
Older adults in 2001 got about 14 millionths of a gram for each kilogram for 5-6 months. A 2004 trial gave 1 milligram twice daily for 12 weeks to men with fat buildup linked to HIV.
You can’t get every safety answer from one group. A short study can’t measure your own long-term risk.